Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib in newly diagnosed FLT3-ITD negative AML
NCT06578247Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd.. Started Nov 2024; status: active, not recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06578247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578247.